241 related articles for article (PubMed ID: 10594016)
1. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis.
Jiang K; Coppola D; Crespo NC; Nicosia SV; Hamilton AD; Sebti SM; Cheng JQ
Mol Cell Biol; 2000 Jan; 20(1):139-48. PubMed ID: 10594016
[TBL] [Abstract][Full Text] [Related]
2. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
Lerner EC; Qian Y; Blaskovich MA; Fossum RD; Vogt A; Sun J; Cox AD; Der CJ; Hamilton AD; Sebti SM
J Biol Chem; 1995 Nov; 270(45):26802-6. PubMed ID: 7592920
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.
Shi Y; Wu J; Mick R; Cerniglia GJ; Cohen-Jonathan E; Rhim JS; Koch CJ; Bernhard EJ
Prostate; 2005 Jan; 62(1):69-82. PubMed ID: 15389805
[TBL] [Abstract][Full Text] [Related]
4. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
Du W; Lebowitz PF; Prendergast GC
Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.
Mazzocca A; Giusti S; Hamilton AD; Sebti SM; Pantaleo P; Carloni V
Mol Pharmacol; 2003 Jan; 63(1):159-66. PubMed ID: 12488548
[TBL] [Abstract][Full Text] [Related]
7. Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors.
Du W; Liu A; Prendergast GC
Cancer Res; 1999 Sep; 59(17):4208-12. PubMed ID: 10485456
[TBL] [Abstract][Full Text] [Related]
8. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
9. The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
Sun SY; Zhou Z; Wang R; Fu H; Khuri FR
Cancer Biol Ther; 2004 Nov; 3(11):1092-8; discussion 1099-1101. PubMed ID: 15467440
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
11. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibition: who are the Aktors?
Bernhard EJ
Cancer Biol Ther; 2004 Nov; 3(11):1099-101. PubMed ID: 15640614
[No Abstract] [Full Text] [Related]
13. Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway.
Law BK; Nørgaard P; Gnudi L; Kahn BB; Poulson HS; Moses HL
J Biol Chem; 1999 Feb; 274(8):4743-8. PubMed ID: 9988711
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
Brassard DL; English JM; Malkowski M; Kirschmeier P; Nagabhushan TL; Bishop WR
Exp Cell Res; 2002 Feb; 273(2):138-46. PubMed ID: 11822869
[TBL] [Abstract][Full Text] [Related]
16. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer.
Yuan ZQ; Sun M; Feldman RI; Wang G; Ma X; Jiang C; Coppola D; Nicosia SV; Cheng JQ
Oncogene; 2000 May; 19(19):2324-30. PubMed ID: 10822383
[TBL] [Abstract][Full Text] [Related]
17. Akt-dependent antiapoptotic action of insulin is sensitive to farnesyltransferase inhibitor.
Park D; Pandey SK; Maksimova E; Kole S; Bernier M
Biochemistry; 2000 Oct; 39(41):12513-21. PubMed ID: 11027130
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
Dai Y; Rahmani M; Pei XY; Khanna P; Han SI; Mitchell C; Dent P; Grant S
Blood; 2005 Feb; 105(4):1706-16. PubMed ID: 15494423
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF.
Girgert R; Wittrock J; Pfister S; Schweizer P
J Cancer Res Clin Oncol; 2003 Apr; 129(4):227-33. PubMed ID: 12700894
[TBL] [Abstract][Full Text] [Related]
20. Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells.
Selleri C; Maciejewski JP; Montuori N; Ricci P; Visconte V; Serio B; Luciano L; Rotoli B
Blood; 2003 Aug; 102(4):1490-8. PubMed ID: 12714496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
